{"id":"BILL-r7423","name":"National Health Amendment (Passive Immunological Products) Bill 2026","slug":"national-health-amendment-passive-immunological-products-bill-2026","collection":"bill","jurisdiction":"commonwealth","status":"in_force","isInForce":true,"actNumber":null,"makingDate":null,"administeringDepartment":null,"currentVersion":{"id":446044,"registerId":"commonwealth-BILL-r7423-current","compilationNumber":null,"startDate":"2026-05-05","status":"royal_assent","reasons":null,"registeredAt":null},"sections":[],"analysis":{"summary":{"status_summary":"The bill received royal assent on 8 April 2026 and is now Act No. 34 of 2026.","complexity_score":2,"likely_questions":["What change does the bill make to the definition of vaccine?","On what date did the bill receive royal assent?"],"complexity_factors":["Updates the definition of vaccine in the National Health Act 1953","Facilitates listing of new and emerging technologies on the National Immunisation Program"],"plain_english_summary":"The bill amends the National Health Act 1953 by updating the definition of vaccine. The purpose is to allow new and emerging technologies to be listed on the National Immunisation Program. This update addresses passive immunological products and similar innovations in the field of immunisation.\n\nIn the House of Representatives the bill was introduced and read a first time on 5 February 2026. The second reading was moved on the same day. Debate on the second reading took place on 10 February 2026 and continued on 11 February 2026 after referral to the Federation Chamber on 10 February 2026. The second reading was agreed to on 11 February 2026. The bill was reported from the Federation Chamber on 12 February 2026 and the third reading was agreed to on that day.\n\nThe bill proceeded to the Senate where it was introduced and read a first time on 3 March 2026. The second reading was moved on 3 March 2026. The second reading was agreed to on 1 April 2026. The third reading was agreed to on 1 April 2026. The bill passed both houses on 1 April 2026.\n\nRoyal assent was given on 8 April 2026. The bill became Act No. 34 of 2026. As a result the amended definition of vaccine now applies. This allows the National Immunisation Program to consider and list products based on new and emerging technologies.\n\nThe changes affect the National Health Act 1953 and the operation of the National Immunisation Program. They impact government health agencies responsible for listing immunisation products. The updated definition applies to passive immunological products and new technologies when considering listings on the program.\n\nNow that the bill has received royal assent there are no further parliamentary steps required. The amendment is in force and the National Immunisation Program can proceed with listings that incorporate passive immunological products and other new technologies as appropriate."},"flash_summary":{"complexity_score":2,"scope_assessment":{"changed":false,"description":"The amendment is narrow and implements its stated purpose: it broadens the statutory meaning of 'vaccine' to include products that confer passive immunity. It does not create additional legislative powers, new funding mechanisms, or new decision‑making bodies. Although the practical reach is broader because many existing provisions refer to 'vaccine', the change remains within the original, declared objective of enabling passive immunological products to be treated as vaccines for existing Commonwealth immunisation arrangements."},"complexity_factors":["Single defined term amended: 'vaccine' in subsection 4(1) of the National Health Act 1953 (one-line substitution).","Commencement straightforward: provision commenced the day after Royal Assent (no staged or conditional commencement).","No new regulatory powers, criteria or bodies created — amendment is definitional only.","Low internal conditionality: no nested exceptions or complex thresholds in the amendment itself.","Potential downstream complexity due to cross-references: many existing provisions and instruments reference 'vaccine', so practical implementation requires cross-checking multiple statutory and administrative instruments.","Operational alignment required with TGA approvals and NIP listing processes (administrative complexity rather than legislative complexity)."],"plain_english_summary":"**What the law changes (mechanics)\n\n- The Act replaces the single legal definition of \"vaccine\" in the National Health Act 1953 with a broader formulation. The new wording reads: \"vaccine means a preparation, including a vaccine or immunising agent, that confers protection to persons through active or passive immunity against disease.\" (Schedule 1, item 1; modifies subsection 4(1) of the National Health Act 1953).\n- The Act commenced the day after it received Royal Assent. (See Commencement provision in the amending Act.)\n\nWho this affects\n\n- Federal health administrators and advisory bodies that run and decide what is on the National Immunisation Program (NIP). Where the National Health Act or NIP rules use the word \"vaccine,\" those references will now include passive immunological products.\n- Manufacturers and suppliers of passive immunological products (for example, monoclonal antibodies or other products that provide passive immunity) because they can now be treated as \"vaccines\" for the purposes of Commonwealth programs that turn on that term.\n- State and territory health services, clinicians and providers who administer products funded or regulated under Commonwealth vaccine frameworks, to the extent those frameworks apply.\n- Taxpayers and the Commonwealth budget, because listing a product as a \"vaccine\" can enable public funding, procurement and distribution.\n\nWhy it matters (purpose claims, and a practical test)\n\n- The government’s stated purpose: enable new and emerging technologies—specifically passive immunological products—to be listed and treated as vaccines under Commonwealth immunisation arrangements (Explanatory Memorandum / second reading speech).\n- Practical effect: the amendment is narrowly mechanical (it swaps one defined term for another), but it changes the legal category that triggers a number of downstream processes (listing on the NIP, procurement, funding, recordkeeping, and any statutory rules that operate when a product is a \"vaccine\"). The Act itself does not create new funding powers or a new listing process; it changes what counts as a vaccine for existing processes (Schedule 1, item 1).\n\nCosts, incentives and trade‑offs\n\n- Who pays: if a passive product is added to the NIP or otherwise funded because it now qualifies as a \"vaccine,\" the cost will fall on the Commonwealth budget and therefore ultimately on taxpayers. (The amendment does not alter the decision-makers for funding; it only alters what may qualify as a vaccine.)\n- Who decides: existing administrative processes and advisory committees that advise on NIP listings retain decision‑making authority; this amendment does not create new decision bodies or criteria — it expands the category of eligible products.\n- Incentives: manufacturers of passive immunological products obtain an incentive to seek NIP listing or other vaccine-oriented procurement because the legal barrier (the narrow definition) has been removed. That creates a concentrated benefit for those manufacturers and a diffuse fiscal cost for taxpayers if listings occur.\n- Price and competition effects: many passive immunological products (for example, monoclonal antibodies) are higher-cost biologics compared with traditional vaccines. If such products are eligible for public funding or guaranteed procurement volumes, that can affect public prices, procurement bargaining power and market structure, potentially favouring larger incumbent producers who can meet scale and cold‑chain requirements.\n- Substitution and clinical choice: clinicians or programs may choose passive immunisation in populations (e.g., immunocompromised people) where active vaccines are less effective. That is a clinical substitution effect rather than a legal one, but the legal change makes such substitution administratively easier when public funding or program rules are involved.\n\nImplementation and administrative risk\n\n- Administrative work required: regulators and the Department of Health will need to update guidance, procurement templates and program rules where the term \"vaccine\" appears. The Therapeutic Goods Administration (TGA) regulatory classification and any clinical guidance will need to be aligned in practice so that a product approved as a therapeutic but now treated as a \"vaccine\" for program purposes is handled coherently.\n- Compliance burden: minimal on individuals; moderate for agencies (budget planning, procurement law, program implementation).\n- Discretion and lobbying risk: because the amendment broadens eligibility without changing listing criteria, industry actors may increase lobbying to secure NIP listing. The benefit of a successful listing would be concentrated (manufacturer revenues) while costs are spread across public expenditure.\n\nNet practical summary\n\n- Mechanically small but legally consequential: a one‑line change to the statutory definition can bring passive immunological products within the scope of Commonwealth vaccine programs and laws. The Act does not itself fund or mandate new products; it changes what may be treated as a \"vaccine\" under existing rules. That widens the set of products eligible for listing, procurement or other vaccine-specific treatment under the National Health Act and associated program rules.\n\n(See Schedule 1, item 1 — substitution of the definition of \"vaccine\" in subsection 4(1) of the National Health Act 1953.)"}},"importantCases":[],"_links":{"self":"/api/acts/national-health-amendment-passive-immunological-products-bill-2026","history":"/api/acts/national-health-amendment-passive-immunological-products-bill-2026/history","analysis":"/api/acts/national-health-amendment-passive-immunological-products-bill-2026/analysis","conflicts":"/api/acts/national-health-amendment-passive-immunological-products-bill-2026/conflicts","importantCases":"/api/acts/national-health-amendment-passive-immunological-products-bill-2026/important-cases","documents":"/api/acts/national-health-amendment-passive-immunological-products-bill-2026/documents"}}